These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 21654755

  • 1. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 2. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 5. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
    Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M.
    Hypertens Res; 2011 Feb; 34(2):268-73. PubMed ID: 21124330
    [Abstract] [Full Text] [Related]

  • 6. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H, Kikuchi F, Ishida T.
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [Abstract] [Full Text] [Related]

  • 7. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T.
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [Abstract] [Full Text] [Related]

  • 8. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group.
    Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
    [Abstract] [Full Text] [Related]

  • 9. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.
    Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
    [Abstract] [Full Text] [Related]

  • 10. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.
    Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
    Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
    [Abstract] [Full Text] [Related]

  • 12. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 13. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 14. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
    Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K.
    Clin Nephrol; 2008 Nov; 70(5):385-92. PubMed ID: 19000538
    [Abstract] [Full Text] [Related]

  • 15. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 16. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T, Saito Y.
    Vasc Health Risk Manag; 2011 Jul; 7():383-90. PubMed ID: 21796252
    [Abstract] [Full Text] [Related]

  • 17. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
    Hayashi K.
    Hypertens Res; 2011 Aug; 34(8):910-2. PubMed ID: 21753772
    [No Abstract] [Full Text] [Related]

  • 18. Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
    Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Takahashi H, Tomino Y.
    Kidney Blood Press Res; 2009 Aug; 32(4):239-49. PubMed ID: 19752573
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 20. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.